Dr. Sergio Giralt, MD – New York, NY

Overview of Dr. Giralt

Dr. Sergio Giralt is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from Central University of Venezuela and has been in practice 34 years. Dr. Giralt accepts several types of health insurance, listed below. He is one of 468 doctors at Memorial Sloan-Kettering Cancer Center who specialize in Oncology. He also speaks multiple languages, including Spanish. He has more than 100 publications and over 500 citings.

Education & Training

• University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1989 - 1993

• TriHealth (Good Samaritan Hospital)Residency, Internal Medicine, 1986 - 1989

• Central University of VenezuelaClass of 1983

Certifications & Licensure

• FL State Medical License 2022 - Present

• NY State Medical License 2010 - 2026

• NJ State Medical License 2021 - 2025

• CT State Medical License 2023 - 2025

• TX State Medical License 1991 - 2025

• OH State Medical License 1989 - 1998

• American Board of Internal Medicine Internal Medicine

Clinical Trials

Publications & Presentations

PubMed

• Symptom clusters and their impact on quality of life in multiple myeloma survivors: Secondary analysis of BMT CTN 0702 trial.

  Brazauskas, R., Flynn, K., D'Souza, A., Krishnan, A., Landau, H., Giralt, S., Pasquini, M., Stadtmauer, E.> ;British Journal of Haematology. 2024 Feb 13

• Transplantation and Cellular Therapy for Older Adults-The MSK Approach.

  Lin, R., Dahi, P., Korc-Grodzicki, B., Shahrokni, A., Jakubowski, A., Giralt, S.> ;Current Hematologic Malignancy Reports. 2024 Feb 9

• Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial.

  Fu, P., Li, G., Malek, E., Kort, J., Metheny, L., Hari, P., Efebera, Y., Callander, N., Qazilbash, M., Giralt, S., Krishnan, A., Stadtmauer, E., Lazarus, H.> ;Transplantation and Cellular Therapy. 2024 Jan 19
• Join now to see all

Journal Articles

• Strategies to Improve Outcomes of Autologous Hematopoietic Cell Transplant in Lymphoma  

  Parastoo B Dahi, Hillard M Lazarus, Sergio A Giralt, Craig S Sauter, Nature

• End-of-Life Care for Older AML Patients Relapsing After Allogeneic Stem Cell Transplant at a Dedicated Cancer Center  

  Sergio A Giralt, Virginia M Klimek, Richard J Lin, Ann A Jakubowski, Esperanza B Papadopoulos, Parastoo B Dahi, Nature

Abstracts/Posters

• Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)

  Sergio A. Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

• Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  Sergio A Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

• Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...

  Sergio Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Approach to the Treatment of the Young, Fit Patient With Myeloma: From Diagnosis to Relapse 

  60th American Society of Hematology Annual Meeting - 12/1/2018

• The Prognostic Calculator Easix Predicts Acute Gvhd, Non-Relapse Mortality and Overall Survival in Adult Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT 

  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

• MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with... 

  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all

Press Mentions

• Actinium Pharmaceuticals Announces Dr. Sergio Giralt to Discuss Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-B via KOL WebinarFebruary 27th, 2023

• Actinium Announces Positive Full Data Results from the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid LeukemiaFebruary 18th, 2023

• Actinium Announces Phase 3 Iomab-B SIERRA Data Accepted for Late-Breaker Presentation at the Transplantation & Cellular Therapy Tandem MeetingsJanuary 12th, 2023

• Join now to see all

Other Languages

Hospital Affiliations

Insurance Accepted

• Aetna Choice POS II
  BCBS Blue Card PPO
  CIGNA HMO
  CIGNA Open Access
  CIGNA PPO
  Empire BCBS HMO
  Empire BCBS PPO
  First Choice
  GHI PPO
  

  Great West PPO
  MVP Healthcare PPO
  ODS Network
  Oxford Health Freedom
  Oxford Health Liberty
  PacificSource Preferred PSN
  Regence Oregon - Preferred Provider Network
  United Healthcare - Direct Choice Plus POS
  United Healthcare - Direct Options PPO
  

• Please verify your coverage with the provider's office directly when scheduling an appointment